Aduro Biotech, Inc.
is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro’s technology platforms, which are designed to harness the body’s natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases.
Aduro’s novel technologies
are in development to induce highly targeted, potent and sustained immune responses against a variety of cancers. We have three diverse immunotherapy platforms – LADD (live, attenuated, double-deleted Listeria mononcytogenes), CDNs (cyclic dinucleotides) and B-select antibodies (B-select) that we believe are the key to staying at the forefront of discovery, development and commercialization of immunotherapies, alone or in combination; that make transformative advances in the treatment of challenging diseases. Read More.
From lab to clinic
Learn how Aduro is developing revolutionary new therapies to treat cancers. Watch the video.